Dexcom Showcases Accuracy, Simplicity and Connectivity of Its CGM Portfolio at ATTD Conference as Access to CGM Expands Globally
February 22 2023 - 12:00AM
Business Wire
- Portfolio includes Dexcom G7, Dexcom ONE and Dexcom G6 and
offers the most powerful, easy to use, connected and covered CGM
options for people living with diabetes around the world.
- The portfolio is built on the unparalleled accuracy of Dexcom
CGM,1 supported by more peer reviewed research than any other CGM
system on the market.
- ATTD conference symposia, posters and presentations continue to
affirm the use of Dexcom CGM is central to optimal diabetes
management when compared to fingersticks and intermittently scanned
CGM.
DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time
continuous glucose monitoring (CGM) for people with diabetes, will
showcase the strength of its CGM portfolio and unveil new clinical
and real-world evidence that continues to demonstrate the
effectiveness of Dexcom CGM at the 16th International Conference on
Advanced Technologies and Treatments for Diabetes held Feb. 22-25,
2023 in Berlin.
“Last year at ATTD we first introduced our expanded portfolio of
Dexcom CGM systems,” said Jake Leach, executive vice president and
chief operating officer of Dexcom. “Almost one year later we are
thrilled to report that Dexcom G7 is already available in eight
countries, Dexcom ONE has played a significant role in helping
expand CGM coverage for millions more people with diabetes and
Dexcom G6 continues to lead the industry in connectivity with
automated insulin delivery systems and digital health apps.”
Dexcom G7, the most powerful and simple CGM, is now
available in the United States, Germany, the United Kingdom,
Ireland, Austria, Hong Kong, New Zealand and South Africa with
additional launches planned in 2023. Feedback from initial Dexcom
G7 users has been extremely positive, with consistent praise for
the 60% smaller wearable,* shortest warmup period on the market†
and more engaging and consumer-friendly mobile app. In addition,
97% of initial users surveyed found Dexcom G7 easy to use.2
Dexcom ONE continues to help expand access to CGM
globally by providing a simple and accurate‡,3 option to meet
the diverse needs of customers, clinicians, and payers around the
world. This has been a key element of the company’s global access
initiatives, which expanded reimbursed coverage to Dexcom CGM
outside the US by more than 3.5 million lives over the past 18
months. From Spain to Estonia and the UK, more and more people
living with diabetes are gaining access to real-time CGM as Dexcom
ONE continues to launch in additional markets.
Dexcom G6 is the most connected CGM system in the world,4
with hundreds of thousands of users now connected to insulin pumps,
pens and digital health apps.§ Dexcom’s ecosystem enables greater
customer choice through partnerships with multiple automated
insulin delivery systems and an API infrastructure that allows
connectivity to several digital health partners, such as Garmin,
Sugarmate, Glooko and Happy Bob. The company’s connectivity
platform is helping make diabetes management more convenient than
ever before for Dexcom G6 users.
In addition, new clinical and real-world evidence continues to
affirm the use of Dexcom CGM is central to optimal diabetes
management, while helping to expand CGM access and use in new
populations. Some of the most recent evidence showcasing the
effectiveness of Dexcom CGM will be highlighted in posters,
presentations and during the Dexcom Symposia at ATTD.
Dexcom Symposia Overview
Dexcom Continues to Lead in CGM Technology Across the
Diabetes Spectrum Thursday, February 23, 2023, 3:00 – 4:30 PM
CET, in Plenary Hall A6 Moderated by Daniel Chernavvsky, MD
- This education program will focus on Dexcom CGM and its use
with both Type 1 and Type 2 diabetes patients. Real world
experience and correlational outcomes of Dexcom G7 and its unique
features will be shared, as well as an introduction to the new
2GO-CGM study, focusing on the use of Dexcom CGM use in Type 2,
intensive and non-intensive insulin treated patients. Finally, the
next generation Dexcom-TypeZero AID algorithm and first in-human
study results will be presented.
Dexcom CGM: Transforming the Course of Care for Type 2
Diabetes Friday, February 24, 2023, 8:00 – 8:50 AM CET, in Hall
A3 Moderated by Noriko Kodani, MD, PhD
- This program reviews recently updated clinical practice
guidelines on rtCGM use in Type 2 diabetes management. There will
be a presentation highlighting new data on the use of rtCGM early
in the course of care for Type 2 diabetes. Additionally, there will
be an examination on how improving access for people with Type 2
diabetes, on less intensive insulin regimens are positioned to
impact utilization and adoption of rtCGM in clinical practice.
Finally, there will be a review of ways to simplify the review of
CGM data, specifically for Type 2 diabetes, and steps that have
been taken to integrate Dexcom Clarity data into electronic health
records for more efficient clinical workflows.
Ahead of the Curve: Inpatient Use of Dexcom G6 and Automated
Insulin Delivery Systems Friday, February 24, 2023, 4:40 – 6:00
PM CET, in Hall A5 Moderated by Erin Cobry, MD
- The emergence of diabetes technology in the hospital holds the
potential to revolutionize glycemic management and change the
standard of care. In this session, participants will learn how
these technologies are fueling the possibility in different patient
populations and hospital settings. The esteemed panel will discuss
continuation of Dexcom rtCGM upon hospital admission and an
associated accuracy analysis in the pediatric population,
preservation of intensive care unit capacity by using Dexcom G6 in
a stepdown unit for patients admitted with diabetic ketoacidosis,
feasibility of an automated insulin delivery system in patients
with Type 1 or Type 2 diabetes in a medical-surgical unit, and
perioperative use of fully closed-loop insulin delivery.
For more information about these presentations and to
register to virtually attend the conference, visit
https://attd.kenes.com/.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe and select parts of Asia/Oceania, Dexcom has emerged as a
leader of diabetes care technology. By listening to the needs of
users, caregivers, and providers, Dexcom works to simplify and
improve diabetes management around the world. For more information
on Dexcom, visit https://www.dexcom.com/en-us/about-dexcom.
*Compared to a prior generation Dexcom CGM System. †Dexcom G7
can complete warmup within 30 minutes, whereas other CGM brands
require up to an hour or longer. ‡Results obtained with Dexcom G6
study, which uses the same applicator and sensor (and algorithm) as
Dexcom ONE. §To learn more about insulin pump integrations and
compatibility with Dexcom CGM Systems, visit
dexcom.com/integrate.
1 Dexcom G7, Dexcom G6 and Dexcom ONE CGM System User Guides. 2
Dexcom, data on file, 2021. 3 Shah V et al. Diabetes Technol Ther.
2018;20(6):428-433. 4 Dexcom, data on file, 2022.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230221005809/en/
Media Contact James McIntosh
619-884-2118 james.mcintosh@dexcom.com
Investor Contact Sean
Christensen 858-203-6657 sean.christensen@dexcom.com
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Aug 2024 to Sep 2024
DexCom (NASDAQ:DXCM)
Historical Stock Chart
From Sep 2023 to Sep 2024